155 related articles for article (PubMed ID: 15989496)
1. Serotonergic modulation and irritable bowel syndrome.
Borman R
Expert Opin Emerg Drugs; 2001 Apr; 6(1):57-68. PubMed ID: 15989496
[TBL] [Abstract][Full Text] [Related]
2. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
De Ponti F; Tonini M
Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
[TBL] [Abstract][Full Text] [Related]
3. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Lewis JH
Drug Saf; 2011 Jul; 34(7):545-65. PubMed ID: 21663331
[TBL] [Abstract][Full Text] [Related]
4. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
Farthing MJ
Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
[TBL] [Abstract][Full Text] [Related]
5. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
6. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
Wagstaff AJ; Frampton JE; Croom KF
Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
8. Rationale for using serotonergic agents to treat irritable bowel syndrome.
Baker DE
Am J Health Syst Pharm; 2005 Apr; 62(7):700-11; quiz 712-3. PubMed ID: 15790796
[TBL] [Abstract][Full Text] [Related]
9. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
Scarpignato C; Pelosini I
Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
[TBL] [Abstract][Full Text] [Related]
10. Tegaserod for the treatment of irritable bowel syndrome.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
[TBL] [Abstract][Full Text] [Related]
11. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
Lembo A; Weber HC; Farraye FA
Drugs; 2003; 63(18):1895-905. PubMed ID: 12930162
[TBL] [Abstract][Full Text] [Related]
12. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
Johanson JF
Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
[TBL] [Abstract][Full Text] [Related]
13. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
Tonini M; Pace F
Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of tegaserod in irritable bowel syndrome management.
Berardi RR
J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152
[TBL] [Abstract][Full Text] [Related]
15. Tegaserod and other serotonergic agents: what is the evidence?
Chey WD
Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
[TBL] [Abstract][Full Text] [Related]
16. The brain-gut axis in irritable bowel syndrome--clinical aspects.
Mach T
Med Sci Monit; 2004 Jun; 10(6):RA125-31. PubMed ID: 15173682
[TBL] [Abstract][Full Text] [Related]
17. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
Gershon MD
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
[TBL] [Abstract][Full Text] [Related]
18. Drug therapy options for patients with irritable bowel syndrome.
Talley NJ
Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
[TBL] [Abstract][Full Text] [Related]
19. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
20. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.
Chey WD; Cash BD
Expert Opin Investig Drugs; 2005 Feb; 14(2):185-93. PubMed ID: 15757394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]